Core Viewpoint - The research highlights the role of MKRN2, an RNA-binding E3 ubiquitin ligase, in selectively inhibiting IL-6 translation, thereby restraining inflammation and autoimmune diseases [3][5][9]. Group 1: Mechanism of Action - MKRN2 binds to IL-6 mRNA and promotes K29 polyubiquitination of the translation initiation coactivator PAIP1 at lysine 179, which blocks PAIP1's interaction with the critical translation regulatory protein eIF4A, thus inhibiting IL-6 mRNA translation [6]. - The study indicates that E3-RBP's role in regulating specific pro-inflammatory cytokines remains unclear, necessitating further investigation [5]. Group 2: Clinical Implications - In clinical samples from patients with ulcerative colitis and rheumatoid arthritis, MKRN2 expression was found to be negatively correlated with IL-6 expression, suggesting its involvement in the progression of inflammatory diseases [8]. - The findings provide new insights into the mechanisms of inflammatory autoimmune diseases and suggest potential therapeutic strategies by interfering with the translation processes of specific pro-inflammatory cytokines [9].

Core Insights - The research team at the Shenzhen Institute of Advanced Technology has made significant advancements in the development of attenuated live vaccines, focusing on the optimization of PROTAR vaccine technology through the diversity of E3 ubiquitin ligases and viral proteins [1][2] Group 1: Research Achievements - The team has established a PROTAR influenza vaccine library and developed PROTAR vaccine 2.0, providing new strategies for safer and more effective attenuated live vaccine development [1] - A unique "life switch" element, PTD, has been designed to control the stability and degradation of viral proteins, which is crucial for reducing viral replication and transforming viruses into potential vaccines [1] Group 2: Technical Developments - The research utilized the diversity of E3 ubiquitin ligases to construct 22 types of PROTAR vaccine strains, expanding the variety of PROTAR vaccines and demonstrating their diversity [2] - PROTAR vaccine 2.0 allows for the PTD element to be loaded at any suitable site on the viral protein, enhancing the technology's applicability across different viruses [2] Group 3: Experimental Validation - Validation experiments in MDCK cells, mouse models, and ferret models demonstrated that PROTAR vaccine 2.0 exhibits good safety, immunogenicity, and cross-immunity protection effects [2] - The universal applicability of PROTAR vaccine 2.0 has been confirmed across various influenza viruses [2]